Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.

Thondam SK, Alusi S, O'Driscoll K, Gilkes CE, Cuthbertson DJ, Daousi C.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):170-2. doi: 10.1097/WNF.0b013e31829fc165.

PMID:
24045609
2.

Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.

Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P.

Clin Neuropharmacol. 2011 Sep-Oct;34(5):179-81. doi: 10.1097/WNF.0b013e3182281b2f.

PMID:
21738024
3.

Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.

Almanzar S, Zapata-Vega MI, Raya JA.

Psychosomatics. 2013 Jul-Aug;54(4):387-91. doi: 10.1016/j.psym.2012.10.002. Epub 2012 Dec 20. No abstract available.

PMID:
23261076
4.

Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.

De Sousa SM, Chapman IM, Falhammar H, Torpy DJ.

Endocrine. 2017 Feb;55(2):618-624. doi: 10.1007/s12020-016-1088-1. Epub 2016 Sep 6.

PMID:
27601019
5.

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O.

Clin Neuropharmacol. 2012 Nov-Dec;35(6):261-5. doi: 10.1097/WNF.0b013e31826e6e6d.

PMID:
23123689
6.

Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.

Höfle G, Gasser R, Mohsenipour I, Finkenstedt G.

Exp Clin Endocrinol Diabetes. 1998;106(3):211-6.

PMID:
9710362
7.

Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.

Jones SE, James RA, Hall K, Kendall-Taylor P.

Clin Endocrinol (Oxf). 2000 Oct;53(4):529-34.

PMID:
11012580
8.

Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.

Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB.

Clin Endocrinol (Oxf). 2014 Jun;80(6):863-8. doi: 10.1111/cen.12375. Epub 2013 Dec 16.

9.

Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.

Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, Sixel-Döring F.

BMC Neurol. 2011 Sep 28;11:117. doi: 10.1186/1471-2377-11-117.

10.

Association of dopamine agonist use with impulse control disorders in Parkinson disease.

Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB.

Arch Neurol. 2006 Jul;63(7):969-73.

11.

Long term follow-up of Parkinson's disease patients with impulse control disorders.

Sohtaoğlu M, Demiray DY, Kenangil G, Ozekmekçi S, Erginöz E.

Parkinsonism Relat Disord. 2010 Jun;16(5):334-7. doi: 10.1016/j.parkreldis.2010.02.006. Epub 2010 Mar 11.

PMID:
20223696
12.

Treating prolactinomas with dopamine agonists: always worth the gamble?

Noronha S, Stokes V, Karavitaki N, Grossman A.

Endocrine. 2016 Feb;51(2):205-10. doi: 10.1007/s12020-015-0727-2. Epub 2015 Sep 4. Review.

PMID:
26336835
13.
14.

Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist.

Auyeung M, Tsoi TH, Tang WK, Cheung CM, Lee CN, Li R, Yeung E.

Parkinsonism Relat Disord. 2011 Sep;17(8):635-7. doi: 10.1016/j.parkreldis.2011.06.001. Epub 2011 Jun 25.

PMID:
21705258
15.

[Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].

Bayard S, Cochen De Cock V, Dauvillers Y.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Jun;9(2):227-35. doi: 10.1684/pnv.2011.0275. Review. French.

PMID:
21690031
16.

Medication-related impulse control and repetitive behaviors in Parkinson's disease.

Voon V, Potenza MN, Thomsen T.

Curr Opin Neurol. 2007 Aug;20(4):484-92. Review.

PMID:
17620886
17.

Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.

Ahlskog JE.

Physiol Behav. 2011 Jul 25;104(1):168-72. doi: 10.1016/j.physbeh.2011.04.055. Epub 2011 May 5. Review.

PMID:
21557955
18.

Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.

Bienfait KL, Menza M, Mark MH, Dobkin RD.

J Clin Neurosci. 2010 Apr;17(4):539-40. doi: 10.1016/j.jocn.2009.09.001. Epub 2010 Feb 19.

19.

The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.

Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR.

J Pediatr Hematol Oncol. 2005 Jun;27(6):326-9.

PMID:
15956887
20.

Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.

Glaser B, Nesher Y, Barziliai S.

J Reprod Med. 1994 Jun;39(6):449-54.

PMID:
7932398

Supplemental Content

Support Center